VKTX Viking Therapeutics, Inc.
Company Analysis
Latest News
🟢 Viking Therapeutics is trading 23.21% up today after positive VK2735 maintenance data
Viking Therapeutics is trading $37.10 (+23.21%) after September 22, 2026, results showed VK2735 patients maintained up to 97% of prior weight loss with...
Viking Reports Positive VK2735 Data Supporting Less Frequent Dosing for Weight Loss Maintenance
Viking Therapeutics announced positive top-line results from its maintenance study of VK2735, a GLP-1/GIP agonist for obesity. The study demonstrated that...
🟢 Viking Therapeutics is trading 32.51% up in pre-market as broader risk-on momentum lifts biotech
Viking Therapeutics is trading 32.51% up at $39.90 after gaining 3.86% on September 21, 2026, with the move appearing mainly tied to continued biotech and...
🟢 Viking Therapeutics is trading 5.8% up in pre-market on continued biotech momentum
Viking Therapeutics is trading at $31.85, up 5.78%, most likely reflecting continued biotech and broader risk-on momentum after strong September 21 equity...
🟢 Viking Therapeutics is trading 4% up today amid broad risk-on rally
Viking Therapeutics is trading 4.02% up now at $30.16, supported by a broad September 21, 2026 risk-on rally as major U.S. indices gained more than 0.5%. -...
Viking's Obesity Drug Clears a Key Hurdle — But Can a $4 Billion Biotech Outrun Lilly and Novo to Market?
Shares surged 12.5% to $33.69 after Viking Therapeutics disclosed that its lead weight-loss drug advanced into Phase 3 trials, a milestone that validates the...
🟢 Viking Therapeutics is trading 12.49% up in after-hours trading after VK2735 advanced into Phase 3
Viking Therapeutics is trading at $33.69 (+12.49%) after reports that VK2735 advanced into Phase 3. - It closed at $29.95, then surged in extended trading on...
🔴 Viking Therapeutics is trading 5.2% down today amid biotech-sector weakness and risk-off macro conditions
Viking Therapeutics is trading at $29.90, down -5.17%, mainly amid biotech-sector weakness and risk-off macro conditions. - No clearly reported negative...
Viking Therapeutics Eyes Weight-Loss Data, BNY Mellon Takes $16M Stake
Viking Therapeutics expects to release early-stage data for its lead weight-loss drug, VK2735, this quarter. The upcoming results evaluate less-frequent and...
🔴 Viking Therapeutics is trading 4.3% down today amid broad risk-off pressure
Viking Therapeutics is trading 4.3% down now at $32.41 as broad risk-off pressure weighs on biotech and other growth-focused sectors. - Investor caution ahead...
🟢 Viking Therapeutics is trading 4.69% up today as XBI gains 2.06%
Viking Therapeutics is trading at $34.79 (+4.69%), primarily on broader biotech strength. - XBI is up 2.06%, alongside a generally positive equity-market...
🔴 Viking Therapeutics falls 4.0% — Biotech Sector Cools Off After Moderna-Sparked Rally
With Biotech (XBI) down 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a pullback after a...
🟢 Viking Therapeutics rises 4.3% — Biotech Sector Surges on Positive mRNA Cancer Vaccine Trial Results
With Biotech (XBI) up 3.7%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, proxied by the XBI ETF, is trading...
🔴 Viking Therapeutics is trading 4.3% down today as sector risk-off sentiment weighs on shares
Viking Therapeutics is trading 4.3% down at $31.70 as broad biotech sector weakness weighs on the stock. • The decline extends a week-long slide following the...
🔴 Viking Therapeutics is trading 6% down today amid broader biotech weakness and risk-off sentiment
Viking Therapeutics is trading at $31.96 (-6.04%) amid broader biotech weakness and a lack of new company-specific catalysts following a sharp morning...
Viking Therapeutics' second quarter 2026 loss per share beats estimates as its Phase 3 obesity trials advance.
Viking Therapeutics reported a smaller-than-expected loss for the second quarter as key clinical trials for its obesity drug candidate, VK2735, progressed as...
🔴 Viking Therapeutics is trading 4.1% down today ahead of its Q2 2026 earnings report
Viking Therapeutics is trading 4.1% down at $33.65 as investors position themselves ahead of the company’s Q2 2026 earnings report scheduled for July 29,...
Viking Therapeutics, Inc. Q2 2026 Earnings Preview: What Analysts Expect on July 29, 2026
Viking Therapeutics is expected to report zero revenue and a consensus loss of $1.21 per share, while its current price of $35.83 sits well below the average...
🔴 Viking Therapeutics is trading 5.0% down
Viking Therapeutics is trading at $35.43, down 5.0% from a comparison close of $37.31 during regular trading. This is a price-action follow-up, so a separate...
Viking Therapeutics, Inc. Q2 2026 Earnings Preview: What Analysts Expect on July 22, 2026
Viking Therapeutics is expected to report a consensus EPS loss of $1.21 on zero revenue for the second quarter of 2026, with its current price of $33.80...